Harris R A, Nease R F
Division of General Internal Medicine, Stanford University, CA, USA.
J Health Econ. 1997 Feb;16(1):113-9. doi: 10.1016/s0167-6296(96)00510-3.
When using cost-effectiveness analyses to prioritize the allocation of health care resources across patients, a standard definition of effectiveness must be used. In an informal review of cost-effectiveness analyses, we found a heterogeneity in the methods used to qualify adjust years of life. Many studies do not account for the morbid conditions that patients experience other than the index condition being studied. These studies systematically overstate health benefit relative to studies that do for comorbidities. We recommend that patient preferences for comorbid conditions be incorporated into analyses to allow a consistent and facile comparison of cost-utility ratios for societal decision making.
在运用成本效益分析来确定医疗保健资源在患者间的分配优先级时，必须使用有效性的标准定义。在对成本效益分析的一次非正式审查中，我们发现用于确定调整生命年的方法存在异质性。许多研究没有考虑患者除所研究的索引疾病之外所经历的其他疾病状况。相对于考虑了合并症的研究，这些研究系统性地高估了健康效益。我们建议将患者对合并症的偏好纳入分析，以便能对成本效用比进行一致且便捷的比较，从而用于社会决策。
